Our shareholders, GlaxoSmithKline and Pfizer, have a strong commitment to the company and want to build upon their heritage and success in developing and providing access to HIV treatments.
We are keen to establish collaborations with businesses, individuals and other organisations in the healthcare community in order to broaden our capability and enhance our performance still further.
One of our first tasks will be to pursue a more collaborative approach on fixed dose combinations and identify an organisation to help develop new treatments for children, using the £10 million of initial funding recently committed to this area.